HDL Particle Count and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder. Reviewed by the ExomeDNA Science Team.
What is HDL particle count?
HDL particles—the carriers informally called 'good cholesterol'—perform reverse cholesterol transport, retrieving cholesterol from peripheral tissues and returning it to the liver for processing and excretion. HDL particle count (HDL-P) quantifies the number of circulating HDL particles, a measure increasingly distinguished from HDL cholesterol concentration (HDL-C) because the two do not always move together. Emerging evidence suggests that HDL-P may better capture cardiovascular protective capacity than HDL-C alone in some contexts, since particle count more directly reflects the number of functional cholesterol-retrieval vehicles available in circulation.
HDL particles are generated through a sequence of biochemical steps: lipid-poor apolipoprotein A-I (apoA-I) accepts cholesterol and phospholipids from peripheral cells via membrane transporters, producing nascent discoidal HDL; the free cholesterol is then esterified by LCAT to form mature spherical HDL particles that can carry their cholesterol cargo to the liver. The number of HDL particles in circulation at any time reflects the balance between particle generation (driven by apoA-I lipidation and triglyceride hydrolysis by LPL), particle remodeling (through CETP, LIPC, and LCAT activity), and particle clearance (through hepatic receptors). Genetic variants across all these steps collectively determine where an individual's HDL-P falls in the population distribution.
This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. ExomeDNA's genetic reports are for wellness and educational purposes only.
The genetics behind HDL particle count
Ninety-five GWAS credible sets—all with established locus-to-gene linkage—implicate an exceptionally diverse set of genes spanning every step of the HDL lifecycle. All top-ranked genes carry established locus-to-gene linkage at individual values above 0.92, reflecting high-confidence mechanistic assignment across a comprehensive genetic map.
CETP (L2G 0.95) encodes cholesteryl ester transfer protein, which mediates the exchange of cholesteryl esters from HDL for triglycerides in apoB-containing lipoproteins (LDL, VLDL). Each exchange cycle depletes HDL of cholesterol and enriches it with triglycerides, shrinking mature spherical HDL and reducing HDL particle number. CETP is the primary driver of HDL-C and HDL-P depletion in circulation: individuals with low or absent CETP activity—common in some East Asian populations due to loss-of-function variants—have HDL-C concentrations five to ten times above population average, demonstrating CETP's central role in HDL cholesterol depletion.
LPL (L2G 0.95) encodes lipoprotein lipase, the enzyme that hydrolyzes triglycerides in VLDL and chylomicrons at the capillary endothelium. As triglycerides are hydrolyzed, the surface components of these particles—phospholipids, free cholesterol, and apolipoproteins including apoA-I—are released into circulation and incorporated into nascent HDL particles. High LPL activity therefore generates more HDL particles by supplying the surface material needed for HDL biogenesis. LPL loss-of-function variants cause hypertriglyceridemia and markedly low HDL-P, while gain-of-function ANGPTL4 loss-of-function variants (which disinhibit LPL) raise HDL by allowing higher effective LPL activity.
ABCA1 (L2G 0.93) encodes the ATP-binding cassette transporter A1, which mediates the efflux of cholesterol and phospholipids from cells to lipid-poor apoA-I—the critical first step in HDL particle biogenesis. ABCA1 is the primary molecular mechanism by which peripheral cells (especially macrophages in atherosclerotic plaques) initiate reverse cholesterol transport. Complete loss of ABCA1 function causes Tangier disease, characterized by virtual absence of plasma HDL, demonstrating its non-redundant role in HDL particle generation. Common ABCA1 variants that modulate efflux efficiency are among the strongest determinants of HDL-P in population studies.
LIPC (L2G 0.95) encodes hepatic lipase, which hydrolyzes phospholipids and triglycerides on circulating HDL particles in the liver. LIPC activity remodels HDL—reducing particle size and enabling hepatic uptake of HDL components—contributing to HDL particle turnover and clearance. Lower LIPC activity is generally associated with higher HDL-P and larger HDL particles.
APOE (L2G 0.96) is present on a subset of HDL particles and mediates their clearance through hepatic LDL receptors and LRP1. APOE isoform effects on HDL-P reflect differences in receptor-binding affinity that alter HDL particle clearance rates, adding a receptor-mediated dimension to the APOE locus's broad influence on lipoprotein metabolism.
APOA2 (L2G 0.96) encodes apolipoprotein A-II, the second most abundant protein on HDL after apoA-I. ApoA-II influences HDL particle size, promotes CETP-mediated cholesteryl ester transfer, and modulates LIPC activity. Higher ApoA-II expression is associated with smaller, more numerous HDL particles.
LCAT (L2G 0.95) encodes lecithin-cholesterol acyltransferase, which esterifies free cholesterol on the HDL surface using phosphatidylcholine as the acyl donor. This reaction converts flat, nascent discoidal HDL into mature spherical HDL—the step that transforms a cholesterol acceptor into a cholesterol carrier. Complete LCAT deficiency produces virtually no mature HDL, establishing this enzyme as essential for the HDL maturation pathway.
ANGPTL4 (L2G 0.95) encodes angiopoietin-like protein 4, an LPL inhibitor secreted by adipose and liver tissue. Loss-of-function ANGPTL4 variants disinhibit LPL, increasing effective triglyceride hydrolysis and consequently raising HDL particle generation rates. ANGPTL4 is under active investigation as a therapeutic target for raising HDL-P and lowering triglycerides.
GWAS breadth: Ninety-five independent GWAS loci—all with established locus-to-gene linkage—identify genes spanning cholesterol efflux (ABCA1), HDL remodeling (CETP, LIPC, LCAT), triglyceride hydrolysis driving HDL biogenesis (LPL, ANGPTL4), apolipoprotein composition (APOA2, APOE, APOB), and hepatic clearance. This represents one of the most comprehensive genetic maps of any circulating lipoprotein phenotype.
CETP biology: Individuals with complete CETP deficiency—seen in some East Asian populations—have HDL-C levels five to ten times above population average, demonstrating CETP's dominant role in depleting HDL of cholesterol. Population variants reducing CETP activity consistently associate with higher HDL-P in large cohort studies.
HDL-P versus HDL-C discordance: HDL particle count and HDL cholesterol concentration can diverge in 20–30% of individuals, particularly in the setting of insulin resistance, hypertriglyceridemia, or elevated CETP activity. In these cases, HDL-P may better reflect the functional reverse cholesterol transport capacity than HDL-C measured on a standard lipid panel.
What the research says
A genome-wide association study of HDL particle concentration (et al., 2022; PMID 35213538) identified 95 credible loci with established locus-to-gene assignment, representing a comprehensive genetic architecture of the HDL lifecycle. The signal spans every step of the HDL pathway: lipid efflux at the cell membrane, particle biogenesis through triglyceride hydrolysis, cholesterol esterification and maturation, remodeling by transfer proteins and lipases, and hepatic clearance through receptor-mediated pathways.
The convergence of independently discovered signals onto well-characterized lipid metabolism genes—CETP, LPL, ABCA1, LCAT, LIPC—validates the biological coherence of the GWAS approach for this trait and provides a mechanistically complete portrait of the genetic regulation of HDL particle number.
Research base: Moderate.
How your HDL particle count affects you
Higher HDL particle count reflects more efficient reverse cholesterol transport capacity—the system responsible for retrieving cholesterol from peripheral tissues and returning it to the liver. In population studies, higher HDL-P consistently associates with reduced cardiovascular susceptibility signals across diverse cohorts, with HDL-P showing stronger associations than HDL-C in some analyses.
| Biological step | Representative gene | Effect on HDL-P |
|---|---|---|
| Cholesterol efflux from cells | ABCA1 | Higher efflux → more nascent HDL generated |
| Triglyceride hydrolysis (HDL biogenesis) | LPL, ANGPTL4 | Higher LPL activity → more HDL surface material |
| HDL cholesterol depletion | CETP | Lower CETP → more cholesterol retained in HDL |
| HDL maturation | LCAT | Higher LCAT → more nascent HDL converted to mature |
| HDL remodeling and clearance | LIPC, APOE | Modulates particle size and hepatic uptake rate |
This page is informational only. For health decisions, consult a qualified clinician.
Working with your profile
HDL particle count is modifiable through both lifestyle and pharmacological means. Regular aerobic exercise raises HDL-P more reliably than almost any other intervention—and does so through multiple mechanisms, including increased LPL activity and apoA-I production. Dietary saturated fat reduction, smoking cessation, and weight loss each contribute independently. Among pharmacological approaches, CETP inhibitors, fibrates (which activate LPL indirectly through PPARα), and niacin all raise HDL-P through mechanism-specific pathways. Genetic background shapes the baseline HDL-P trajectory; lifestyle interventions can meaningfully shift the distribution above that baseline.
Related traits and genes
- HDL cholesterol (HDL-C) — the cholesterol concentration within HDL particles; shares most of the same genetic regulators as HDL-P but can diverge in individuals with hypertriglyceridemia or high CETP activity
- Triglycerides — ANGPTL4 and LPL are shared genetic regulators across HDL-P and triglyceride GWAS, reflecting the metabolic coupling between triglyceride hydrolysis and HDL biogenesis
- LDL cholesterol — APOE and APOB influence the LDL-HDL metabolic interaction through shared lipoprotein receptor and transfer pathways
Frequently asked questions
What is CETP and how does it affect HDL particle count?
CETP (cholesteryl ester transfer protein) exchanges cholesteryl esters from HDL for triglycerides in LDL and VLDL particles. Each exchange cycle removes cholesterol from HDL and replaces it with triglycerides, reducing HDL size and ultimately lowering HDL particle number as triglyceride-enriched HDL is more rapidly cleared. Individuals with genetically low CETP activity have much higher HDL-C and HDL-P, while high CETP activity depletes HDL. CETP inhibitors have been developed as potential cardiovascular drugs; their clinical benefit has been mixed in trials, despite large HDL-raising effects.
Why does LPL activity determine HDL particle count?
Lipoprotein lipase (LPL) hydrolyzes triglycerides in VLDL and chylomicrons at the capillary endothelium. As these particles are processed, their surface components—phospholipids, free cholesterol, and apolipoprotein A-I—are released into circulation and reutilized to assemble nascent HDL particles. LPL activity is therefore a direct upstream driver of HDL biogenesis: higher effective LPL activity generates more nascent HDL particles per unit time. ANGPTL4 inhibits LPL; loss-of-function ANGPTL4 variants disinhibit LPL and raise HDL-P, establishing this axis as a target for pharmacological intervention.
What is ABCA1 and why is it essential for HDL production?
ABCA1 encodes the ATP-binding cassette transporter A1, which translocates cholesterol and phospholipids across the cell membrane to lipid-poor apoA-I molecules. This is the founding step of HDL biogenesis—without ABCA1, apoA-I cannot become lipidated and nascent HDL cannot form. Complete ABCA1 loss-of-function causes Tangier disease, a rare condition characterized by near-zero plasma HDL and cholesterol accumulation in tonsils and other tissues. Common ABCA1 variants that modulate efflux efficiency have graded effects on HDL-P across the population, with each allele dose shifting the particle count distribution.
What is LCAT and how does it mature HDL particles?
LCAT (lecithin-cholesterol acyltransferase) esterifies free cholesterol on the surface of nascent, discoidal HDL using a fatty acid from phosphatidylcholine. This reaction has two consequences: it converts the flat nascent HDL into a spherical mature HDL capable of storing large amounts of cholesteryl esters in its core, and it creates a concentration gradient that drives continued cholesterol efflux from peripheral cells. LCAT deficiency prevents HDL maturation, resulting in accumulation of abnormal discoidal particles and very low circulating HDL-P and HDL-C.
Is HDL particle count a better predictor than HDL cholesterol?
Population studies suggest that HDL-P and HDL-C measure related but distinct aspects of HDL biology. In settings where the two are concordant—most individuals—they have similar predictive value. In individuals where they diverge (particularly those with hypertriglyceridemia, insulin resistance, or metabolic syndrome), HDL-P tends to show stronger associations with cardiovascular outcomes in some analyses. This is because HDL-P more directly reflects the number of functional cholesterol-retrieval vehicles in circulation, while HDL-C can remain normal even when particle count is reduced if the remaining particles are simply cholesterol-enriched.
This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. ExomeDNA's genetic reports are for wellness and educational purposes only.